Global Cancer Care

Emerging Global Leaders in Biosimilar Development: Regulatory Guidance and Cost Impact

Biologics play a key role in cancer treatment and are the principal components of many therapeutic regimens. However, they require complex manufacturing processes, resulting in high cost...


Bridging the Survivorship Care Gap for Young Adult Survivors of Thyroid Cancer

Although thyroid cancer is among the five most common carcinomas diagnosed in adolescents and young adults (AYAs) between the ages of 15 and 39—thyroid cancer is more common...

Solid Tumors

Does Reducing the Starting Dose of Sorafenib Affect Outcomes in Hepatocellular Carcinoma?

In a retrospective study reported in the Journal of Clinical Oncology, Reiss et al found that reducing the starting dose of sorafenib (Nexavar) was associated with noninferior overall survival...


More Top Stories

Prostate Cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Global Cancer Care

Conquer Cancer Foundation and ASCO International Development and Education Award

Applications Being Accepted Through October 31, 2017  THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) provides support for early-career oncologists in low-and middle-income countries and facilitates the sharing of knowledge between these oncologists and ASCO members. The program pairs...


Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson

The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of president at The University of Texas MD Anderson Cancer Center in Houston. The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...

Breast Cancer

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Cost of Care

Addressing the Societal Impact of Financial Toxicity

Most discussions about “financial toxicity” center on the cancer patient, but there is also a societal toxicity, which has far-reaching consequences. Coming up with answers to this growing problem has vexed health-care experts over the past decade. In an effort to gather opinions on this vital...

Your Monthly Gift Can Have a Huge Impact

By contributing a monthly gift to the Conquer Cancer Foundation (CCF), you can make a dramatic difference as we work to build a world free from the fear of cancer. An automatic charge to your credit card each month is the easiest way to complete your monthly donation. Secure and convenient, a...

Whole-Genome Sequencing Reveals Breast Cancers With Mismatch-Repair Deficiencies

Cancers caused by mismatch repair (MMR)-deficiency involve gene mutations that affect the ability of the cell to repair the mistakes that may occur during the DNA replication process. MMR-deficient tumors have 10 to 100 times more mutations than tumors with intact MMR pathways. A study...

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Award for Early Career Scientists in New York: Applications Open October 2, 2017

The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000/year—for up to 3 years—to enable them to pursue...


ESMO 2017: KEYNOTE-045: Updated Results Support Pembrolizumab as Second-Line Treatment in Advanced Urothelial Cancer

Mature results from the KEYNOTE-045 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA37_PR) confirmed significantly longer survival in patients with advanced urothelial cancer who received the checkpoint inhibitor pembrolizumab after initial...